The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.


Robert E. Coleman, MD, FRCP, FRCPE
Medical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom

Javier Cortés, MD, PhD
Ramón y Cajal University Hospital
Madrid, Spain

Sunil Verma, MD, MSEd, FRCPC
Tom Baker Cancer Centre
University of Calgary
Calgary, Alberta, Canada

Activity Details

Credit Type: None
Release Date: November 10, 2016
Expiration Date: November 9, 2017
Estimated Time to Complete Activity: 30 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

This breast cancer thought leader discussion, with associated slide deck and eNewsflash, will provide participants with valuable updates and expert perspectives on exciting new data on the treatment of advanced breast cancer released at the 2016 European Oncology Congress in Copenhagen.


#LBA1_PR First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC): First results from the phase III MONALEESA-2 study
#LBA13 Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC)
#LBA14_PR FALCON: A phase III randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer
#LBA15 Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER+/HER2- advanced breast cancer (ABC)
#LBA18 A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
#222O BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
#225PD Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): Results from PALOMA-2

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Evaluate combinations of targeted and endocrine therapy for the first-line and second-line treatment of ER-positive, HER2-negative advanced breast cancer
  • Describe the role of cyclins and cyclin dependent kinases (CDKs) in the biology of ER-positive disease, and differentiate the range of developmental CDK4/6 inhibitors
  • Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options

Target Audience

This educational activity is specifically designed for medical oncologists, translational scientists, and other healthcare professionals interested in and/or involved in the treatment of breast cancer.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.


This activity is provided by prIME Oncology.


This educational activity is supported by a grant from Novartis Oncology.

Contact Information for Questions about the Activity

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.